In the clinical trials world, an inefficient study start-up has very real consequences. Studies that miss their deadlines for site election, feasibility, enrolment, or activation end up with skyrocketing costs. In fact, Cutting Edge Info puts the cost of trial delays at as much as $8 million lost revenue for each day a drug is delayed.
Virginie Schau, site startup expert at DrugDev, discusses strategies and tactics to ensure that sponsors have the most efficient and successful study startup possible.
- To create a tailored and proactive approach to study startup
- Why proactive planning supported by technology to monitor startup and study surveillance is an essential component to study startup